Immunocore Partners with BMS to Develop IMC-F106C in the P-III (PRISM-MEL301) Trial for the Treatment of Melanoma
Shots:
- Immunocore & BMS have signed a clinical trial collaboration and supply agreement to evaluate the combination of IMC-F106C and nivolumab as 1L treatment of advanced melanoma
- Under the collaboration, Immunocore will be responsible for the funding of P-III study investigating the combination, while BMS will supply nivolumab for the same
- The P-III (PRISM-MEL301) study evaluates IMC-F106C + nivolumab, nivolumab alone & fixed-dose of nivolumab + relatlimab, based on the country in previously untreated, HLA-A*02:01 positive, advanced melanoma patients (n=90). Study will test two doses of IMC-F106C (40mcg & 160mcg) in first 60 patients after which one F106C dose regimen will be discontinued
Ref: Immunocore | Image: Immunocore
Related News:- Immunocore Entered into an Agreement with Gadeta to Develop Gamma Delta TCR ImmTAC for Solid Tumors
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
